Kalaris Therapeutics, Inc. made available an updated corporate presentation on March 9, 2026, for use at The Leerink Partners Global Healthcare Conference and other conferences. The presentation provides updates on timelines for reporting data from the Phase 1b/2 multi-ascending dose clinical trial of TH103 and initiating Phase 3 clinical development, along with other clinical operations updates and cash runway guidance into Q4 2027.
Key takeaways
Updated corporate presentation dated March 9, 2026, attached as Exhibit 99.1
Presentation for upcoming meetings at The Leerink Partners Global Healthcare Conference and other conferences
Updates on timelines for reporting data from ongoing Phase 1b/2 multi-ascending dose clinical trial of TH103
Updates on timelines for initiating Phase 3 clinical development of TH103
Preliminary Phase 1b/2 data expected in 1H 2027
$50MM oversubscribed private placement in December 2025 with investors including ADAR1 Capital Management, Coastlands Capital, Invus, RTW Investments, Samsara BioCapital, Woodline Partners LP
Sufficient cash runway to fund company into Q4 2027